Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-09T17:10:30.915Z Has data issue: false hasContentIssue false
  • English
  • Français

Triclabendazole: new skills to unravel an old(ish) enigma

Published online by Cambridge University Press:  12 April 2024

I. Fairweather
I. Fairweather*
Affiliation:
Parasite Proteomics and Therapeutics Research Group, School of Biology and Biochemistry, The Queen's University of Belfast, Medical Biology Centre, 97, Lisburn Road, Belfast, BT9 7BL, UK
*
*Fax: +44 28 90975877, E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Triclabendazole was introduced in the early 1980s for the treatment of Fasciola hepatica infections in livestock. Due to its high activity against immature flukes, it has become established as the principal anti-fluke drug on the market. More recently, triclabendazole has been used to treat human cases of fascioliasis and is now the drug of choice for this infection, too. Resistance to triclabendazole was first reported in 1995 in a field population in Australia and, since that time, resistant populations have been identified in several countries in Europe. Parallel to the spread of resistance has been a sharp increase in the prevalence of fascioliasis, which has been attributed largely to climate changes. Consequently, farmers are faced with an alarming scenario, as none of the other fasciolicides on the market possess such high activity against the damaging immature stages of fluke. The main aim of this review is to assess current understanding of the mechanism of action of triclabendazole against the fluke and the mechanism by which the fluke has become resistant to it. The use of triclabendazole against animal and human infections is summarized and suggestions are given on ways to deal with resistance. Gaps in the knowledge of various aspects of its use are highlighted and this may serve to open up future research areas.

Type
Review Article
Information
Journal of Helminthology , Volume 79 , Issue 3 , September 2005 , pp. 227 - 234
Copyright
Copyright © Cambridge University Press 2005

References

Abo-Madyan, A.A., Morsy, T.A., Motawea, S.M. & Morsy, A.T. (2004) Clinical trial of Mirazid in treatment of human fascioliasis, Ezbet El-Bakly (Tamyia Center) Al-Fayoum Governate. Journal of the Egyptian Society of Parasitology 34, 807–818.Google Scholar
Alvarez, L.I., Mottier, M.L. & Lanusse, C.E. (2004) Comparative assessment of the access of albendazole, fenbendazole and triclabendazole to Fasciola hepatica: effect of bile in the incubation medium. Parasitology 128, 73–81.CrossRefGoogle ScholarPubMed
Alvarez, L., Solana, H., Mottier, L., Virkel, G., Fairweather, I. & Lanusse, C. (2005) Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology (in press).Google Scholar
Alvinerie, M. & Galtier, P. (1986) Assay of triclabendazole and its main metabolites in plasma by high-performance liquid chromatography. Journal of Chromatography 374, 409–414.CrossRefGoogle ScholarPubMed
Anon. (1995) Resistance to fluke drug found on Sligo farm. Irish Farmers’ Journal 2 18 March.Google Scholar
Anon. (1998) Report of the Scottish Agricultural College's Veterinary Science Division. Veterinary Record 143, 653–654.Google Scholar
Apt, W., Aguilera, X., Vega, F., Miranda, C., Zulantay, I., Perez, C., Gabor, M. & Apt, P. (1995) Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. American Journal of Tropical Medicine and Hygiene 52, 532–535.CrossRefGoogle ScholarPubMed
Bennett, J.L. & Köhler, P. (1987) Fasciola hepatica: action in vitro of triclabendazole on immature and adult stages. Experimental Parasitology 63, 49–57.CrossRefGoogle ScholarPubMed
Borgsteede, F.H.M., Moll, L., Vellema, P. & Gaasenbeek, C.P.H. (2005) Lack of reversion in triclabendazole-resistant Fasciola hepatica . Veterinary Record 156, 350–351.CrossRefGoogle ScholarPubMed
Botros, S., William, S., Ebeid, F., Cioli, D., Katz, N., Day, T.A. & Bennett, J.L. (2004) Lack of evidence for an antischistosomal activity of myrrh in experimental animals. American Journal of Tropical Medicine and Hygiene 71, 206–210.CrossRefGoogle ScholarPubMed
Botros, S., Sayed, H., El-Dusoki, H., Sabry, H., Rabie, I., El-Ghannam, M., Hassanein, M., El-Wahab, Y.E. & Engels, D. (2005) Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni -infected school children and households. American Journal of Tropical Medicine and Hygiene 72, 119–123.CrossRefGoogle ScholarPubMed
Boray, J.C. (1994) Disease of domestic animals caused by flukes . 49 pp. Food and Agricultural Organization of the United Nations, Rome.Google Scholar
Boray, J.C., Crowfoot, P.D., Strong, M.B., Allison, J.R., Schellenbaum, M., Von Orelli, M. & Sarasin, G. (1983) Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Veterinary Record 113, 315–317.CrossRefGoogle ScholarPubMed
Büscher, G., Bowen, F.L., Strong, M.B., Allison, J.R. & Richards, R.J. (1987) Extension of the prepatent period of Fasciola hepatica in infected animals following treatment with triclabendazole. Veterinary Record 120, 460–461.CrossRefGoogle ScholarPubMed
Büscher, G., Bowen, F.L., Strong, M.B. & Crowfoot, P.D. (1999) Efficacy of triclabendazole, its metabolites and other compounds in sheep. 17th International Conference of the WAAVP, Copenhagen, 15–19 August 1999 (abstract c7.40)Google Scholar
Calvopiña, M., Guderian, R.H., Paredes, W., Chici, M. & Cooper, P.J. (1998) Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Transactions of the Royal Society of Tropical Medicine and Hygiene 92, 566–569.CrossRefGoogle ScholarPubMed
Calvopiña, M., Guderian, R.H., Paredes, W. & Cooper, P.J. (2003) Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 451–454.CrossRefGoogle ScholarPubMed
Carr, A.W., McCracken, R.O. & Stillwell, W.H. (1993) Uncoupling of rat liver mitochondrial oxidative phosphorylation by the fasciolicide triclabendazole and its sulfoxide and sulfone metabolites. Journal of Parasitology 79, 198–204.CrossRefGoogle ScholarPubMed
Coles, G.C. & Stafford, K.A. (2001) Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica . Veterinary Record 148, 723–724.CrossRefGoogle ScholarPubMed
Coles, G.C., Rhodes, A.C. & Stafford, K.A. (2000) The activity of closantel against adult triclabendazole-resistant Fasciola hepatica Veterinary Record 146, 504.CrossRefGoogle Scholar
Crompton, D.W.T. (1999) How much human helminthiasis is there in the world?. Journal of Parasitology 85, 397–403.CrossRefGoogle ScholarPubMed
Fairweather, I. & Boray, J.C. (1999) Mechanisms of fasciolicide action and drug resistance in Fasciola hepatica. pp. 225–276 in Dalton, J.P. (ED.) Fasciolosis . Wallingford, Oxon CAB International.Google Scholar
Fairweather, I. & Boray, J.C. (1999) Fasciolicides: efficacy, actions, resistance and its management. Veterinary Journal 158, 81–112.CrossRefGoogle ScholarPubMed
Fairweather, I., Holmes, S.D. & Threadgold, L.T. (1984) Fasciola hepatica: motility responses to fasciolicides in vitro . Experimental Parasitology 57, 209–224.CrossRefGoogle ScholarPubMed
Farag, H.F. (1998) Human fascioliasis in some countries of the Eastern Mediterranean Region. Eastern Mediterranean Health Journal 4, 156–160.CrossRefGoogle Scholar
Favennec, L., Jave-Ortiz, J., Gargala, G., Lopez-Chegne, N., Ayoub, A. & Rossignol, J.F. (2003) Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Alimentary Pharmacology and Therapeutics 17, 265–270.CrossRefGoogle ScholarPubMed
Fetterer, R.H. (1986) The effect of albendazole and triclabendazole on colchicine binding in the liver fluke Fasciola hepatica . Journal of Veterinary Pharmacology and Therapeutics 9, 49–54.CrossRefGoogle ScholarPubMed
Foreyt, W.J. (1989) Efficacy of triclabendazole against experimentally induced Fascioloides magna infections in sheep. American Journal of Veterinary Research 50, 431–432.Google ScholarPubMed
Gaasenbeek, C.P.H., Moll, L., Cornelissen, J.B.W.J., Vellema, P. & Borgsteede, F.H.M. (2001) An experimental study on triclabendazole resistance of Fasciola hepatica in sheep. Veterinary Parasitology 95, 37–43.CrossRefGoogle Scholar
Gilles, H.M. & Hoffman, P.S. (2002) Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends in Parasitology 18, 95–97.CrossRefGoogle ScholarPubMed
Haridy, F.M., El Garhy, M.F. & Morsy, T.A. (2003) Efficacy of Mirazid (Commiphora molmol) against fascioliasis in Egyptian sheep. Journal of the Egyptian Society of Parasitology 33, 917–924.Google ScholarPubMed
Hennessy, D.R., Lacey, E., Steel, J.W. & Prichard, R.K. (1987) The kinetics of triclabendazole disposition in sheep. Journal of Veterinary Pharmacology and Therapeutics 10, 64–72.CrossRefGoogle ScholarPubMed
Hernández-Campos, A., Ibarra-Velarde, F., Vera-Montenegro, Y., Rivera-Fernández, N. & Castillo, R. (2002) Synthesis and fasciolicidal activity of 5-chloro-2-methylthio-6-(1-naphthyloxy)-1H-benzimidazole. Chemical and Pharmaceutical Bulletin 50, 649–652.CrossRefGoogle ScholarPubMed
Hopkins, D.R. (1992) Homing in on helminths. American Journal of Tropical Medicine and Hygiene 46, 626–634.CrossRefGoogle Scholar
Ibarra, F., Vera, Y., Quiroz, H., Cantó, J., Castillo, R., Hernández, A. & Ochoa, P. (2004) Determination of the effective dose of an experimental fasciolicide in naturally and experimentally infected cattle. Veterinary Parasitology 120, 65–74.CrossRefGoogle ScholarPubMed
Kerboeuf, D. Blackhall, W., Kaminsky, R. & von Samson-Himmelstjerna, G. (2003) P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. International Journal of Antimicrobial Agents 22, 332–346.CrossRefGoogle ScholarPubMed
Kwa, M.S.G., Veenstra, J.G. & Roos, M.H. (1994) Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in β-tubulin isotype 1. Molecular and Biochemical Parasitology 63, 299–303.CrossRefGoogle ScholarPubMed
Lacey, E. (1988) The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. International Journal for Parasitology 18, 885–936.CrossRefGoogle ScholarPubMed
Laird, P.P. & Boray, J.C. (1992) Human fascioliasis successfully treated with triclabendazole. Australian and New Zealand Journal of Medicine 22, 45–47.CrossRefGoogle ScholarPubMed
Lipkowitz, K.B. & McCracken, R.O. (1991) A molecular modelling approach to in vivo efficacy of triclabendazole. Journal of Parasitology 77,998–1005.CrossRefGoogle ScholarPubMed
Mansour-Ghanaei, F., Shafaghi, A. & Fallah, M. (2003) The effect of metronidazole in treating human fascioliasis. Medical Science Monitor 9, 127–130.Google ScholarPubMed
Mas-Coma, M.S., Esteban, J.G. & Bargues, M.D. (1999) Epidemiology of human fascioliasis: a review and proposed new classification. Bulletin of the World Health Organization 77, 340–346.Google ScholarPubMed
McCoy, M.A., Fairweather, I., Brennan, G.P., Kenny, J.M. & Forbes, A.B. (2005) The efficacy of nitroxynil and triclabendazole administered synchronously against juvenile triclabendazole-resistant Fasciola hepatica in sheep. Research in Veterinary Science 78, 33.Google Scholar
Mitchell, G.B.B., Maris, L. & Bonniwell, M.A. (1998) Triclabendazole-resistant liver fluke in Scottish sheep. Veterinary Record 143, 399.Google ScholarPubMed
Mohammed Ali, N.A.K., Bogan, J.A., Marriner, S.E. & Richards, R.J. (1986) Pharmacokinetics of triclabendazole alone or in combination with fenbendazole in sheep. Journal of Veterinary Pharmacology and Therapeutics 9, 442–445.Google ScholarPubMed
Moll, L., Gaasenbeek, C.P.H., Vellema, P. & Borgsteede, F.H.M. (2000) Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in the Netherlands. Veterinary Parasitology 91, 153–158.CrossRefGoogle ScholarPubMed
Montenegro, Y.V., Ibarra Velarde, F., Liébano Hernández, E., Quiroz Romero, H., Castillo Bocanegra, R., Hernández Campos, A. & Ochoa Galván, P. (2004) Efficacy of an experimental fasciolicide against immature and mature Fasciola hepatica in artificially infected calves. Parasitology Research 92, 211–214.CrossRefGoogle Scholar
Mottier, L., Virkel, G., Solana, H., Alvarez, L., Salles, J. & Lanusse, C.E. (2004) Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidised metabolites into Fasciola hepatica . Xenobiotica 34, 1043–1057.CrossRefGoogle ScholarPubMed
Overend, D.J. & Bowen, F.I. (1995) Resistance of Fasciola hepatica to triclabendazole. Australian Veterinary Journal 72, 275–276.CrossRefGoogle ScholarPubMed
Richter, J., Knipper, M., Göbels, K. & Häusinger, D. (2002) Fascioliasis. Current Treatment Options in Infectious Diseases 4, 313–317.Google Scholar
Rivera, N., Ibarra, F., Zepeda, A., Fortoul, T., Hernández, A., Castillo, R. & Cantó, G. (2004) Tegumental surface changes in adult Fasciola hepatica following treatment in vitro and in vivo with an experimental fasciolicide. Parasitology Research 93, 283–286.CrossRefGoogle ScholarPubMed
Rivera, N., Ibarra, F., Zepeda, A., Fortoul, T., Cantó, G., Hernandez, A. & Castillo, R. (2005) The effect of the 5-chloro-2-methylthio-6-(1-naphtyloxy)-1 H -benzimidazole on the tegument of immature Fasciola hepatica in their natural host. Parasitology Research 95, 379–382.CrossRefGoogle Scholar
Robinson, M.W., Hoey, E.M., Fairweather, I., Dalton, J.P., McGonigle, S. & Trudgett, A. (2001) Characterisation of a β-tubulin gene from the liver fluke, Fasciola hepatica . International Journal for Parasitology 31, 1264–1268.CrossRefGoogle ScholarPubMed
Robinson, M.W., Trudgett, A., Hoey, E.M. & Fairweather, I. (2002) Triclabendazole-resistant Fasciola hepatica: β-tubulin and response to in vitro treatment with triclabendazole. Parasitology 124, 325–338.CrossRefGoogle ScholarPubMed
Robinson, M.W., Lawson, J., Trudgett, A., Hoey, E.M. & Fairweather, I. (2004) The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica . Parasitology Research 92, 205–210.CrossRefGoogle ScholarPubMed
Robinson, M.W., McFerran, N., Trudgett, A., Hoey, E.M. & Fairweather, I. (2004) A possible model of benzimidazole binding to β-tubulin disclosed by invoking an interdomain movement. Journal of Molecular Graphics and Modelling 23, 275–284.CrossRefGoogle Scholar
Rojo-Vásquez, F.A. (2004) The present status of helminth infections in small ruminants in Spain: prevalence, anthelmintic resistance and some considerations on their control. Proceedings of the IX European Multicolloquium of Parasitology, Valencia, July 2004 , p. 267.Google Scholar
Rossignol, J.-F, Abaza, H. & Friedman, H. (1998) Successful treatment of human fascioliasis with nitazoxanide. Transactions of the Royal Society of Tropical Medicine and Hygiene 92, 103–104.CrossRefGoogle ScholarPubMed
Santra, P.K., Prasad, A. & Ghosh, S. (1999) Efficacy of triclabendazole against experimental fasciolosis in lambs. Journal of Veterinary Parasitology 13, 111–122.Google Scholar
Sanyal, P.K. & Gupta, S.C. (1996) Efficacy and pharmacokinetics of triclabendazole in buffalo with induced fasciolosis. Veterinary Parasitology 63, 75–82.CrossRefGoogle ScholarPubMed
Savioli, L., Chitsulo, L. & Montresor, A. (1999) New opportunities for the control of fascioliasis. Bulletin of the World Health Organization 77, 300.Google Scholar
Sheir, Z., Nasr, A.A., Massoud, A., Salama, O., Badra, G.A., El-Shennawy, H., Hassan, N. & Hammad, S.M. (2001) A safe, effective, herbal antischistosomal therapy derived from myrrh. American Journal of Tropical Medicine and Hygiene 65, 700–704.CrossRefGoogle ScholarPubMed
Smeal, M.G. & Hall, C.A. (1983) The activity of triclabendazole against immature and adult Fasciola hepatica infections in sheep. Australian Veterinary Journal 60, 329–331.CrossRefGoogle ScholarPubMed
Soliman, O.E., El-Arman, M., Abdul-Samie, E.R., El-Nemr, H.I. & Masoud, A. (2004) Evaluation of myrrh (Mirazid) therapy in fascioliasis and intestinal schistosomiasis in children: immunological and parasitological study. Journal of the Egyptian Society of Parasitology 34, 941–966.Google ScholarPubMed
Stitt, A.W. & Fairweather, I. (1992) Spermatogenesis in Fasciola hepatica : an ultrastructural comparison of the effects of the anthelmintic, triclabendazole (“Fasinex”) and the microtubule inhibitor, tubulozole. Invertebrate Reproduction and Development 22, 139–150.CrossRefGoogle Scholar
Stitt, A.W. & Fairweather, I. (1993a) Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). Parasitology Research 79, 529–536.CrossRefGoogle ScholarPubMed
Stitt, A.W. & Fairweather, I. (1993b) Fasciola hepatica: the effect of the microtubule inhibitors colchicine and tubulozole-C on the ultrastucture of the adult fluke. Parasitology 107, 297–309.CrossRefGoogle Scholar
Stitt, A.W. & Fairweather, I. (1994) The effect of the sulphoxide metabolite of triclabendazole (“Fasinex”) on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica . Parasitology 108, 555–567.CrossRefGoogle ScholarPubMed
Stitt, A.W. & Fairweather, I. (1996) Fasciola hepatica : disruption of the vitelline cells in vitro by the sulphoxide metabolite of triclabendazole. Parasitology Research 82, 333–339.CrossRefGoogle ScholarPubMed
Stitt, A.W., Fairweather, I. & Mackender, R.O. (1995) The effect of triclabendazole (“Fasinex”) on protein synthesis by the liver fluke, Fasciola hepatica . International Journal for Parasitology 25, 421–429.CrossRefGoogle ScholarPubMed
Talaie, H., Emami, H., Yadegarinia, D., Nava-Ocampo, A.A., Massoud, J., Azmoudeh, M. & Mas-Coma, S. (2004) Randomized trial of a single, double and triple dose of 10 mg kg of a human formulation of triclabendazole in patients with fascioliasis. Clinical and Experimental Pharmacology and Physiology 31, 777–782.CrossRefGoogle ScholarPubMed
Thomas, I., Coles, G.C. & Duffus, K. (2000) Triclabendazole-resistant Fasciola hepatica in southwest Wales. Veterinary Record 146, 200.Google ScholarPubMed
Turner, K., Armour, J. & Richards, R.J. (1984) Anthelmintic efficacy of triclabendazole against Fasciola hepatica in sheep. Veterinary Record 114, 41–42.CrossRefGoogle ScholarPubMed
Walker, S.M., McKinstry, B., Boray, J.C., Brennan, G.P., Trudgett, A., Hoey, E.M., Fletcher, H. & Fairweather, I. (2004) Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitology Research 94, 427–438.CrossRefGoogle ScholarPubMed
Wessely, K., Reischig, H.L., Heinerman, M. & Stempka, R. (1988) Human fascioliasis treated with triclabendazole (Fasinex) for the first time. Transactions of the Royal Society of Tropical Medicine and Hygiene 82, 743–745.CrossRefGoogle ScholarPubMed
Wolstenholme, A.J., Fairweather, I., Prichard, R., von Samson-Himmelstjerna, G. & Sangster, N.C. (2004) Drug resistance in veterinary helminths. Trends in Parasitology 20, 469–476.CrossRefGoogle ScholarPubMed